AIs can improve the prognosis of hormone receptor-positive breast cancer (4), but the continuous reduction of estrogen levels can lead to aromatase inhibitor-associated bone loss (AIBL), which is associated with bone metabolic dysfunction, arthralgia, osteopenia, and osteoporosis (5). This evidence concerns the gene CYP19A1 and Osteopenia.